scholarly journals Hubungan antara Fatigue, Jumlah CD4, dan Kadar Hemoglobin pada Pasien yang Terinfeksi Human Immunodeficiency Virus (HIV)

2018 ◽  
Vol 5 (3) ◽  
Author(s):  
Kusman Ibrahim ◽  
Yusshy Kurnia H ◽  
Laili Rahayuwati ◽  
Baiq Emi Nurmalisa ◽  
Siti Ulfah Rifa’atul Fitri
Keyword(s):  
Human Immunodeficiency Virus ◽  
Cell Count ◽  
Pearson Correlation ◽  
Hemoglobin Level ◽  
Aids Patients ◽  
Cd4 Cell Count ◽  
Fatigue Score ◽  
Immunodeficiency Virus ◽  
Cd4 Cell ◽  
Hiv Aids

Keberadaan Human Immunodeficiency Virus (HIV) di dalam tubuh secara terus menerus menyebabkan gangguan pada hampir semua sistem tubuh yang berdampak pada munculnya gejala kelelahan (fatigue). Fatigue banyak dilaporkan pada penderita HIV/AIDS dengan prevalensi berkisar antara 20% sampai 60%. Penelitian ini bertujuan menguji hubungan antara fatigue dengan jumlah CD4 dan kadar Hb pada pasien HIV/AIDS. Sebanyak 77 responden direkrut secara purposif di sebuah Klinik Rawat Jalan Rumah Sakit di Kota Bandung. Fatigue diukur menggunakan kuesioner HIV Related Fatigue Score (HRFS). Data yang terkumpul dianalisis menggunakan uji pearson correlation. Hasil penelitian menunjukkan terdapat hubungan yang bermakna antara fatigue dengan jumlah CD4 dalam darah (r = -.289, p< 0.05) dan kadar Hb (r = -.349, p< 0.05). Selain itu, kadar Hb memiliki hubungan yang bermakna dengan jumlah CD4 pada pasien HIV/AIDS (r = .360, p < .01). Hasil penelitian ini mengindikasikan perlunya monitoring kadar CD4 dan Hb secara berkala dan melakukan intervensi untuk mengatasi penurunan Hb dan CD4 sesegera mungkin sehingga dapat mencegah agar fatigue tidak berkelanjutan.Kata kunci: CD4, fatigue, hemoglobin, HIV/AIDS. The Correlation of Between Fatigue, CD4 Cell Count, and Hemoglobin Level among HIV/AIDS PatientsAbstractThe existence of Human Immunodeficiency Virus (HIV) in the body continuously causes disruption in almost all body systems that impact on the emergence of symptoms of fatigue. Fatigue was widely reported in HIV/AIDS patients with prevalence ranging from 20% to 60%. This study examined the relationship between fatigue and CD4 cell count and hemoglobin levels in HIV/AIDS patients. A total of 77 respondents were recruited purposively in Outpatient Clinic, General Hospital Bandung City. Fatigue was measured using the HIV Related Fatigue Score (HRFS) questionnaire. The collected data were analyzed using pearson correlation product moment. The results showed there were significant relationship between fatigue and CD4 count in blood (r = -.289, p< 0.05) and hemoglobin level (r = -.349, p< 0.05). In addition, CD4 had significantly correlation with Hb (r = .360, p < .01). The results of this study indicated that nurses or health care providers need to periodically monitor the CD4 and Hb levels and provide early intervention to manage the hemoglobin and CD4 cell count at optimum levels to prevent prolonging fatiguel.Keywords: CD4, fatigue, hemoglobin, HIV/AIDS.

scholarly journals Frequency of Cytomegalovirus Viral Load in Iranian Human Immunodeficiency Virus-1-Infected Patients with CD4+ Counts <100 Cells/mm3

Intervirology ◽  
2021 ◽  
pp. 1-5
Author(s):  
Mohammad Reza Jabbari ◽  
Hoorieh Soleimanjahi ◽  
Somayeh Shatizadeh Malekshahi ◽  
Mohammad Gholami ◽  
Leila Sadeghi ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Viral Load ◽  
Cell Count ◽  
Previous History ◽  
Cd4 Count ◽  
Cd4 Cell Count ◽  
Cell Counts ◽  
Immunodeficiency Virus ◽  
Cd4 Cell ◽  
Hiv 1

<b><i>Objectives:</i></b> The aim of present work was to assess cytomegalovirus (CMV) viremia in Iranian human immunodeficiency virus (HIV)-1-infected patients with a CD4+ count &#x3c;100 cells/mm<sup>3</sup> and to explore whether CMV DNA loads correlate with CD4+ cell counts or associated retinitis. <b><i>Methods:</i></b> This study was conducted at the AIDS research center in Iran on HIV-1-infected patients with CD4+ count &#x3c;100 cells/mm<sup>3</sup>, antiretroviral therapy-naive, aged ≥18 years with no previous history of CMV end-organ disease (CMV-EOD). <b><i>Results:</i></b> Thirty-nine of 82 patients (47.56%) had detectable CMV viral load ranging from 66 to 485,500 IU/mL. CMV viral load in patients with retinitis ranges from 352 to 2,720 IU/mL, and it was undetectable in 2 patients. No significant associations between CMV viremia and CD4+ cell count was found (<i>p</i> value = 0.31), whereas significant association of CMV viremia in HIV-infected patients with retinitis was found (<i>p</i> &#x3c; 0.02). <b><i>Conclusions:</i></b> We estimated the frequency of CMV viral load infection in Iranian HIV-1-infected patients with a CD4+ cell count &#x3c;100 mm<sup>3</sup>/mL in the largest national referral center for HIV-1 infection in Iran. Further research is required on the relevance of CMV viral load in diagnostic and prognostic value of CMV-EOD.

scholarly journals Hepatitis C treatment uptake and response among human immunodeficiency virus/hepatitis C virus-coinfected patients in a large integrated healthcare system

2019 ◽  
Vol 30 (7) ◽  
pp. 689-695 ◽  
Author(s):  
Jennifer O Lam ◽  
Leo B Hurley ◽  
Scott Chamberland ◽  
Jamila H Champsi ◽  
Laura C Gittleman ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Drug Abuse ◽  
Cell Count ◽  
Hcv Treatment ◽  
Cd4 Cell Count ◽  
Treatment Uptake ◽  
Immunodeficiency Virus ◽  
Cd4 Cell

U.S. guidelines recommend that patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) be prioritized for HCV treatment with direct-acting antiviral agents (DAAs), but the high cost of DAAs may contribute to disparities in treatment uptake and outcomes. We evaluated DAA initiation and effectiveness in HIV/HCV-coinfected patients in a U.S.-based healthcare system during October 2014–December 2017. Of 462 HIV/HCV-coinfected patients, 276 initiated DAAs (70% cumulative proportion treated over three years). Lower likelihood of DAA initiation was observed among patients with Medicare (government-sponsored insurance) versus commercial insurance (adjusted rate ratio [aRR] = 0.62, 95% CI = 0.46–0.84), patients with drug abuse diagnoses (aRR = 0.72, 95% CI = 0.54–0.97), patients with CD4 cell count <200 cells/µl versus ≥500 (aRR = 0.45, 95% CI = 0.23–0.91), and patients without prior HCV treatment (aRR = 0.68, 95% CI = 0.48–0.97). There were no significant differences in DAA initiation by age, gender, race/ethnicity, socioeconomic status, HIV transmission risk, alcohol use, smoking, fibrosis level, HIV RNA levels, antiretroviral therapy use, hepatitis B infection, or number of outpatient visits. Ninety-five percent of patients achieved sustained virologic response (SVR). We found little evidence of sociodemographic disparities in DAA initiation among HIV/HCV-coinfected patients, and SVR rates were high. Efforts are needed to increase DAA uptake among coinfected Medicare enrollees, patients with drug abuse diagnoses, patients with low CD4 cell count, and patients receiving first-time HCV treatment.

Effects of CD4 cell count and antiretroviral therapy on mucocutaneous manifestations among HIV/AIDS patients in Yunnan, China

2019 ◽  
Vol 59 (3) ◽  
pp. 308-313 ◽  
Author(s):  
Yu‐Ye Li ◽  
Shi‐Han Yang ◽  
Rui‐Rui Wang ◽  
Jun‐Ting Tang ◽  
Hong‐Mei Wang ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Cell Count ◽  
Aids Patients ◽  
Cd4 Cell Count ◽  
Cd4 Cell ◽  
Hiv Aids

scholarly journals Human Immunodeficiency Virus Type 1 Disease Progression, CCR5 Genotype, and Specific Immune Responses

1998 ◽  
Vol 5 (4) ◽  
pp. 463-466 ◽  
Author(s):  
Ubaldo Visco-Comandini ◽  
Catharina Hultgren ◽  
Christina Broström ◽  
Markus Birk ◽  
Soo Kim ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Immune Responses ◽  
Cell Count ◽  
Disease Progression ◽  
Wild Type ◽  
Cd4 Cell Count ◽  
Immunodeficiency Virus ◽  
Cd4 Cell ◽  
Hiv 1

ABSTRACT The correlation among the presence of a 32-bp deletion in the CC-chemokine receptor 5 (CCR5) gene, disease progression, and human immunodeficiency virus type 1 (HIV-1)-specific immune responses was analyzed for a cohort of 79 Caucasian HIV-1-infected patients. The CCR5 genotype (CCR5/CCR5 = wild type/wild type or Δ32CCR5/CCR5 = 32-bp deletion/wild type) in peripheral blood mononuclear cells was determined by PCR, followed by sequencing of both wild-type and Δ32CCR5 gene fragments. HIV-1-specific humoral responses to gp41 and V3MN peptides were determined by enzyme immunoassays. The prevalence of the Δ32CCR5 allele was lower among 37 patients with rapid progression (progression to AIDS or to a CD4 cell count of <200 × 106/liter in less than 9 years; P < 0.01) compared to that for 42 patients with slow progression (no AIDS and CD4 cell count of >200 × 106/liter after at least 9 years from infection) or to that for 25 non-HIV-1-infected Swedish blood donors (P < 0.05). No differences were observed in the wild-type CCR5sequences between the different groups of patients. For three analyzed patients, the 32-bp Δ32CCR5 gene deletions were identical. The antibody titers against gp41 and a V3MNpeptide in patients with the Δ32CCR5/CCR5 genotype were not significantly different from those in pair-matchedCCR5/CCR5 controls. However, in 13 analyzed patients, a stronger serum neutralizing activity was associated with the Δ32CCR5/CCR5 genotype. Thus, a CCR5/CCR5genotype correlates with a shortened AIDS-free HIV-1 infection period and possibly with a worse neutralizing activity, without an evident influence on the antibody response to two major antigenic regions of HIV-1 envelope.

Sign in / Sign up

Export Citation Format

Share Document